Table 2. Outcomes for different triage arms of hrHPV testing positive in rural sites and urban sites.
| Variables | n (%) (95% CI) | ||||||
| Rural sites | Urban sites | ||||||
| Direct COLP (N=852) | LBC triage (N=218) | VIA/VILI triage (N=480) | Direct COLP for HPV 16/18+ (N=408) | Direct COLP for other hrHPV subtypes+ (N=571) | LBC triage for other hrHPV subtypes+ (N=568) | ||
| hrHPV, high-risk human papillomavirus; CIN, cervical intraepithelial neoplasia; 95% CI, 95% confidence interval; COLP, referral to colposcopy without triage; LBC, liquid-based cytology; VIA/VILI, visual inspection with acetic acid and Lugol’s iodine. | |||||||
| Baseline screening | |||||||
| Triage positivity rates | 852 (100) | 48 (22.02) (16.52−27.52) |
130 (27.08) (23.11−31.06) |
408 (100) | 571 (100) | 183 (32.22) (28.38−36.06) |
|
| Colposcopy referral rates | 852 (100) | 41 (18.81) (13.62−23.99) |
127 (26.46) (22.51−30.40) |
354 (86.76) (82.40−89.17) |
571 (100) | 155 (27.29) (23.63−30.95) |
|
| CIN2+ detection rates | 62 (7.28) (5.53−9.02) |
13 (5.96) (2.82−9.11) |
16 (3.33) (1.73−4.94) |
67 (16.42) (12.83−20.02) |
42 (7.36) (5.21−9.50) |
13 (2.29) (1.06−3.52) |
|
| CIN3+ detection rates | 38 (4.46) (3.07−5.85) |
6 (2.75) (0.58−4.92) |
5 (1.04) (0.13−1.95) |
43 (10.54) (7.56−13.52) |
13 (2.28) (1.05−3.50) |
5 (0.88) (0.11−1.65) |
|
| Colposcopy referral number for detecting one CIN2+ |
14 | 3 | 8 | 6 | 14 | 12 | |
| Colposcopy referral number for detecting one CIN3+ |
23 | 7 | 26 | 9 | 44 | 31 | |
| 24-month follow-up screening | |||||||
| Adherence rates | 605 (71.01) (67.87−73.96) |
169 (77.52) (71.53−82.56) |
345 (71.88) (67.69−75.71) |
239 (58.58) (53.74−63.26) |
385 (67.43) (63.48−71.14) |
406 (71.48) (67.63−75.04) |
|
| Follow-up screening positivity rates | 227 (37.52) (33.66−41.38) |
75 (44.38) (36.89−51.87) |
129 (37.39) (32.29−42.50) |
99 (41.42) (35.18−47.67) |
149 (38.70) (33.84−43.57) |
165 (40.64) (35.86−45.42) |
|
| Colposcopy referral rates | 168 (27.77) (24.20−31.34) |
69 (40.83) (33.70−48.36) |
110 (31.88) (27.19−36.98) |
88 (36.82) (30.71−42.93) |
123 (31.95) (27.49−36.76) |
138 (33.99) (29.55−38.73) |
|
| CIN2+ detection rates | 22 (3.64) (2.14−5.13) |
7 (4.14) (1.14−7.15) |
6 (1.74) (0.36−3.12) |
6 (2.51) (0.53−4.49) |
6 (1.56) (0.32−2.8) |
8 (1.97) (0.62−3.32) |
|
| CIN3+ detection rates | 12 (1.98) (0.87−3.09) |
1 (0.59) (0−1.75) |
1 (0.29) (0−0.86) |
2 (0.84) (0−1.99) |
0 | 1 (0.25) (0−0.73) |
|
| Colposcopy referral number for detecting one CIN2+ |
8 | 10 | 18 | 15 | 21 | 18 | |
| Colposcopy referral number for detecting one CIN3+ |
14 | 65 | 106 | 44 | − | 137 | |
| 24-month cumulative follow-up screening | |||||||
| CIN2+ detection rates | 84 (9.86) (8.03−12.04) |
20 (9.17) (6.02−13.75) |
22 (4.58) (3.05−6.84) |
73 (17.89) (14.48−21.91) |
48 (8.41) (6.40−10.97) |
21 (3.70) (2.43−5.59) |
|
| CIN3+ detection rates | 50 (5.87) (4.48−7.65) |
7 (3.21) (1.56−6.48) |
6 (1.25) (0.57−2.70) |
45 (11.03) (8.35−14.44) |
13 (2.28) (1.34−3.86) |
6 (1.06) (0.49−2.29) |
|